| Objective:In this study,the application of Indacaterol/Glycopyrronium Bromide(fixed-dose combination FDC)to COPD patients in stable stage was used to observe its clinical efficacy and the influence of serum inflammatory factors.Compared with open triple combination,the clinical significance of Indacaterol/Glycopyrronium FDC was understood to provide reference for clinical medication.Methods:Sixty patients in COPD stable COPD group C and D,outpatient department of Respiratory and Critical Care Medicine,Affiliated Hospital of Inner Mongolia University for Nationalities,from June 2020 to January 2022,were included and randomly divided into two groups.Observation group 30 patients were treated with inhaled Indacaterol/Glycopyrronium FDC(110/50μg)for 1 month.The control group was treated with Tiotropium(18μg)+ Budesonide/Formoterol FDC(320/9μg)for 1month.The differences of FEV1,FVC,PEF,CAT,CCQ,m MRC and serum inflammatory indexes between the two groups before and after treatment were compared.The two groups were divided into C and D subgroups according to the 2020 GOLD Guidelines for further comparative analysis.The incidence of adverse reactions in enrolled COPD patients was recorded during follow-up.Results:1.Analysis of baseline level between the observation group and the control group showed that there were no significant differences in age,gender,BMI,COPD history,smoking history,number of acute exacerbations in the past year,and baseline of GOLD group between the two groups(P>0.05),and the baseline of general information was consistent.2.There were statistically significant differences in CCQ,CAT and m MRC between the two groups before and after treatment(P<0.001);After treatment,there was no significant difference between the two groups(P>0.05).3.There were statistically significant differences in FEV1,FVC and PEF between the two groups before and after treatment(P<0.001);After treatment,the improvement degree was similar between the two groups without statistical difference(P>0.05).4.There were statistically significant differences in serum IL-8,IL-17 and VAP-1 before and after treatment(P<0.001).After treatment,the decrease of control group was more obvious than observation group,but there was no statistical difference(P>0.05).5.In subgroup C and D analysis,there were statistically significant differences in FEV1,FVC,PEF,CCQ,CAT,m MRC,IL-8,IL-17 and VAP-1 between the two groups before and after treatment(P<0.05);After treatment,FEV1,FVC,PEF,CCQ,CAT and m MRC were compared between the two groups,and the improvement degree was similar.Serum IL-8,IL-17 and VAP-1 decreased more significantly in the control group,but there was no statistical difference(P>0.05).6.There was 1 case in the observation group with dry mouth symptoms,and 2 cases in the control group with headache,palpitations and other symptoms,without serious adverse events,and the incidence of adverse reactions in the two groups was 3.45% and 6.90%,respectively.Research Conclusions:1.Indacaterol/Glycopyrronium FDC and Tiotropium combined with Budesonide/Formoterol FDC can effectively improve lung function and quality of life in stable COPD patients.2.Indacaterol/Glycopyrronium FDC and Tiotropiam combined with Budesonide/Formoterol FDC can reduce serum IL-8,IL-17 and VAP-1levels in stable COPD patients to a certain extent,thus reducing airway inflammation;The change of its expression level has certain clinical significance to judge COPD exacerbation.3.In the C and D subgroup analysis,it was further verified that.Indacaterol/Glycopyrronium FDC and Tiotropiam combined with Budesonide/Formoterol FDC could improve lung function,quality of life and reduce serum IL-8,IL-17 and VAP-1 levels,providing a choice for clinical medication.4.During the follow-up period,the two groups had few adverse drug reactions,which had good safety and clinical application value. |
PDF Full Text Request